Jeffrey T Bates Selected Research

Cerebral Small Vessel Diseases

1/2016

APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey T Bates Research Topics

Disease

4	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 01/2016
2	Albuminuria 01/2018 - 11/2017
2	Hypertension (High Blood Pressure) 01/2017 - 01/2016
2	Thrombosis (Thrombus) 01/2014 - 11/2004
1	Acidosis 01/2018
1	Cerebral Small Vessel Diseases 01/2016
1	Chronic Disease (Chronic Diseases) 09/2015
1	Venous Thrombosis (Deep-Vein Thrombosis) 11/2004
1	Multiple Endocrine Neoplasia Type 2a (MEN 2) 11/2004

Drug/Important Bio-Agent (IBA)

1	Antihypertensive Agents (Antihypertensives)IBA 01/2018
1	Bicarbonates (Hydrogen Carbonate)IBA 01/2018
1	Triglycerides (Triacylglycerol)IBA 11/2017
1	Apolipoprotein L1IBA 07/2017
1	Hemoglobins (Hemoglobin)IBA 01/2016
1	Indicators and Reagents (Reagents)IBA 01/2016
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016
1	DiureticsIBA 09/2015
1	reteplase FDA Link 11/2004
1	Tissue Plasminogen Activator (Alteplase)FDA Link 11/2004
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 11/2004

Therapy/Procedure

1	Therapeutics 01/2017
1	Stents 01/2014
1	Surgical Amputation (Amputations) 01/2014
1	Catheters 11/2004
1	Thrombectomy 11/2004